Jeito is a global leading investment company. Our mission: identify & support the next generation of pioneering entrepreneurs in the field of medical innovation
Hier matin sur @RadioClassique, j’ai eu le plaisir de revenir sur le rôle et la mission de @Jeito_life dans l'écosystème de l'innovation en santé.
2/3 des maladies connues aujourd'hui n'ont pas de traitement. Nous voulons accélérer pour les patients ! https://t.co/FWkgZdGeBM
Join us at #VCF24 - starting tomorrow in Amsterdam ⏰
Our panel on Exit Strategies will ask ⤵️
🔸 How do current market conditions impact exit strategies and LP expectations?
🔸 Can we anticipate a return of IPOs in Europe soon?
🔸 What strategies are LPs and GPs using to maximise exit value in a volatile market?
With Saman Sadeghi of Van Campen Liem, @FallgrenStefan of Skandia Mutual Life Insurance Company, Mitesh Prabari of @hamilton_lane and Ksenija Pavletic of @Jeito_life.
Register now and check out the agenda 👉 https://t.co/OlfeGP2qsa
#VentureCapital
We would like to congratulate our co-founder José-Alain Sahel for being awarded the @WolfPrize_ for Medicine.
The prize honors scientists and artists worldwide for their outstanding achievements in advancing science and the arts for the betterment of humanity.
#WolfPrize
Since our first investment in #CatalYm, we have been convinced that company was developing a promising new therapy approach to treat cancer.
The recent and very impressive data reported by CatalYm makes us even more committed to renewing our support to its talented team. 👏
We are thrilled to share Jeito's participation in the $150 million Series D financing of #Catalym, our portfolio company developing novel immunotherapies to fight cancer.
This new investment confirms CatalYm’s strong progress and potential.
Read more 👉 https://t.co/3vFSzuds0i
"Privatizing Research to Share Innovation?": Don't miss this exceptional conference at #ReAix featuring @RafaeleTordjman, Founder and CEO of Jeito.
Follow online the discussions, Saturday, July 6th at 5 PM 👉 https://t.co/q0g6Saakob
The acquisition of HI-Bio by Biogen has been completed. Together, we will be advancing our clinical development plans to deliver innovative treatments to patients in need. Follow @Biogen for the latest news and read about the acquisition: https://t.co/vAxZXUW8ew
🎙️ @RafaeleTordjman était sur @bfmbusiness pour revenir sur les 2 cessions de Jeito cette semaine : Hi-Bio et EyeBio.
Elles illustrent le succès de la stratégie de notre fonds et la forte demande pour des médicaments innovants pour des maladies sans solution thérapeutique ⤵️
📰 « Deux cessions majeures en une semaine »
A lire dans @Le_Figaro le décryptage de la stratégie de Jeito qui a conduit aux cessions des deux entreprises de notre portefeuille : @HIBiosciences à @Biogen et EyeBio à @Merck.
👉 https://t.co/jlsyD3HJbf
Jeito Capital enchaîne les «success stories».
La société d’investissement cède sa participation dans EyeBio à Merck dans le cadre d’une transaction pouvant atteindre les 3 milliards de dollars. #privateequity
https://t.co/lZ8GVC87iT
Through this new successful exit, @Jeito_life demonstrates how its unique investment strategy and collective expertise bring value to the company, the patients and the investors.
I wish the whole EyeBio team great success with @Merck!
#FasterFortThePatient#privateequity
🚀 Second exit in a week! We are thrilled to announce the acquisition of Jeito’s portfolio company EyeBio by @Merck for a potential value of $3 billion.
This new exit validates further Jeito’s unique and differentiated investment model.
Read more 👉 https://t.co/Zl6tKu8Zaz
🗞️ Check out this article by @BioCentury on @biogen's acquisition of @HIBiosciences from Jeito.
Paul Bonanos highlights the exceptional quality of Hi-Bio's immunology and the significant value creation milestone achieved in the benefit of the patients👇https://t.co/y1M8CKJwc9
👏Congratulations to our portfolio company @SparingVision for being selected once again in the #FT120 Index, highlighting the 120 most promising French companies with the potential to become global leaders in their markets. Proud to support your journey!
🚀 SparingVision is honored to be part of the prestigious French Tech 120 for the 4th consecutive year! 🏆 This recognition underscores our commitment to innovation and growth. Thank you to @LaFrenchTech for this recognition as one of 120 most successful French start-ups!
18 months after Jeito’s initial investment, this exit is evidence of Jeito’s unique investment strategy of targeting pharma demand, selectively sourcing the best opportunities, and validating Jeito’s leading position within a syndicate of high-quality global investors. All proud!
We are thrilled to announce that our portfolio company @HIBiosciences has been acquired by @biogen Inc for up to $1.8 billion.
This successful exit validates Jeito’s unique investment strategy focused on value-creation and patient benefit.
👉 https://t.co/EF3lMMhn3f
#AI opens a new era of therapeutic innovations.
At the #FutureOfFinance Conference, I shared convictions on AI as a must have to accelerate therapeutic innovation for the benefit of patients.
We can go faster for thousands of patients with high unmet needs!
Save the date! 📅Jeito will be at BioEquity Europe in San Sebastian from May 12-14.
Rachel Mears and Ksenija Pavletic, Partners at Jeito Capital, will engage in two insightful roundtable discussions designed for innovative #biopharma companies. ⤵️ #privateequity
We are delighted to announce the appointment of Sarah Leroy who is taking the newly created position of Secretary General, responsible for managing Legal and Financial Affairs, Compliance, Human Resources, and ESG. She joins Jeito's executive committee.
👉 https://t.co/oF5GdTncUW